ArticlePloS one2011
Tumor-derived exosomes confer antigen-specific immunosuppression in a murine delayed-type hypersensitivity model.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it, 121 citations in OpenAlex.
- The clinical importance of the host anti-tumour reaction patterns in regional tumour draining lymph nodes in patients with locally advanced resectable gastric cancer: a systematic review and meta-analysis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2023Pooled it
- Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies.PLoS pathogens · 2013Trial
- Orchestrating organotropism: miRNA-driven mechanisms of site-specific metastasis in triple-negative breast cancer (Review).Oncology letters · 2026Review
- The role of exosomes in immunopathology and potential therapeutic implications.Cellular & molecular immunology · 2025Review
- Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies.Stem cell research & therapy · 2025Review
- Potential Effect of Extracellular Vesicles in Clinical Settings of Lymphoma.Indian journal of clinical biochemistry : IJCB · 2025Review
- The theragnostic advances of exosomes in managing leukaemia.Journal of cellular and molecular medicine · 2024Review
- Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-β signaling.Frontiers of medicine · 2024Article
- Tumor immune escape: extracellular vesicles roles and therapeutics application.Cell communication and signaling : CCS · 2024Review
- Small extracellular vesicle TGF-β in cancer progression and immune evasion.Cancer gene therapy · 2023Review
- Review
- Review
- Tumor-Derived Extracellular Vesicles in Cancer Immunoediting and Their Potential as Oncoimmunotherapeutics.Cancers · 2022Review
- Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- Dendritic cells a critical link to alveolar bone loss and systemic disease risk in periodontitis: Immunotherapeutic implications.Periodontology 2000 · 2022Review
- Tumor-Derived Exosomes in Tumor-Induced Immune Suppression.International journal of molecular sciences · 2022Review
- Tumor-derived extracellular vesicles modulate innate immune responses to affect tumor progression.Frontiers in immunology · 2022Review
- Exosomal miR-29b of Gut Origin in Patients With Ulcerative Colitis Suppresses Heart Brain-Derived Neurotrophic Factor.Frontiers in molecular biosciences · 2022Article
- Review
- Thromboangiitis obliterans plasma-derived exosomal miR-223-5p inhibits cell viability and promotes cell apoptosis of human vascular smooth muscle cells by targeting VCAM1.Annals of medicine · 2021Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Exosomes are endosome-derived small membrane vesicles that are secreted by most cell types including tumor cells. Tumor-derived exosomes usually contain tumor antigens and have been used as a source of tumor antigens to stimulate anti-tumor immune responses. However, many reports also suggest that tumor-derived exosomes can facilitate tumor immune evasion through different mechanisms, most of which are antigen-independent. In the present study we used a mouse model of delayed-type hypersensitivity (DTH) and demonstrated that local administration of tumor-derived exosomes carrying the model antigen chicken ovalbumin (OVA) resulted in the suppression of DTH response in an antigen-specific manner. Analysis of exosome trafficking demonstrated that following local injection, tumor-derived exosomes were internalized by CD11c+ cells and transported to the draining LN. Exosome-mediated DTH suppression is associated with increased mRNA levels of TGF-β1 and IL-4 in the draining LN. The tumor-derived exosomes examined were also found to inhibit DC maturation. Taken together, our results suggest a role for tumor-derived exosomes in inducing tumor antigen-specific immunosuppression, possibly by modulating the function of APCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.